Novartis Collaborates with Biofourmis To Offer Digital Therapeutics for Managing Heart Failures
Shots:
- Novartis will access Biofourmis' lead digital therapeutics- BiovitalsHF to manage patients with heart failure across Asia- with a potential plan to expand it globally
- The focus of the collaboration is to improve clinical outcomes utilizing Biofourmis' BiovitalsHF along with Biovitals Analytics Engine to identify early signs of HF exacerbations- enabling early interventions in patients with HF with a reduced ejection fraction
- Additionally- Biofourmis acquires Biovotion including its Everion biosensor- combining Biovotion's wearables with Biofourmis' digital therapeutics platform and its AI-driven predictive analytics to offer the most comprehensive digital therapeutics solution for the patients
Source 1- Source 2 to read full press release/ article | Ref: PRNewswire- PRNewswire | Image: Twin Cities Business
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com